Yelena Kovtun

5.6k total citations · 1 hit paper
44 papers, 4.1k citations indexed

About

Yelena Kovtun is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Yelena Kovtun has authored 44 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Radiology, Nuclear Medicine and Imaging, 24 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Yelena Kovtun's work include Monoclonal and Polyclonal Antibodies Research (24 papers), HER2/EGFR in Cancer Research (20 papers) and Cancer therapeutics and mechanisms (8 papers). Yelena Kovtun is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (24 papers), HER2/EGFR in Cancer Research (20 papers) and Cancer therapeutics and mechanisms (8 papers). Yelena Kovtun collaborates with scholars based in United States, Ukraine and Netherlands. Yelena Kovtun's co-authors include Jen Sheen, Wan-Ling Chiu, Guillaume Tena, Victor S. Goldmacher, Wayne C. Widdison, Walter A. Blättler, Charlene A. Audette, Robert J. Lutz, Ravi Chari and Hans K. Erickson and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Yelena Kovtun

42 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Functional analysis of oxidative stress-activated mitogen-activated protein kinase cascade in plants

2000 1.1k citations Yelena Kovtun, Wan-Ling Chiu et al. profile →

Peers

Countries citing papers authored by Yelena Kovtun

Since Specialization

Citations

This map shows the geographic impact of Yelena Kovtun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yelena Kovtun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yelena Kovtun more than expected).

Fields of papers citing papers by Yelena Kovtun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yelena Kovtun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yelena Kovtun. The network helps show where Yelena Kovtun may publish in the future.

Co-authorship network of co-authors of Yelena Kovtun

This figure shows the co-authorship network connecting the top 25 collaborators of Yelena Kovtun. A scholar is included among the top collaborators of Yelena Kovtun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yelena Kovtun. Yelena Kovtun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A bispecific anti-MUC16/anti-death receptor 5 antibody achieves effective and tumor-selective death receptor 5-mediated tumor regression 2025 ·Scientific Reports ·Victor S. Goldmacher, (unknown), Ravi Chari, Yelena Kovtun	0
2	Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication 2024 ·PubMed ·Victor S. Goldmacher, (unknown), Yelena Kovtun	1
3	Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation 2019 ·Bioconjugate Chemistry ·Chen Bai, (unknown), Alan Wilhelm, (unknown), Erin K. Maloney, Rassol Laleau, Lauren Harvey, Katie E. Archer, Dilrukshi Vitharana, Sharlene Adams, Yelena Kovtun, Michael L. Miller, Ravi Chari, Thomas A. Keating, Nicholas C. Yoder	20
4	CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia 2018 ·Haematologica ·(unknown), Charlene A. Audette, Yelena Kovtun, Naval Daver, Sa A. Wang, Sherry Pierce, Sergej Konoplev, (unknown), Jeffrey L. Jorgensen, Marina Konopleva, Patrick A. Zweidler‐McKay, L. Jeffrey Medeiros, Hagop M. Kantarjian, Elias Jabbour, Joseph D. Khoury	55
5	A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells 2018 ·Blood Advances ·Yelena Kovtun, Gregory E. Jones, Sharlene Adams, Lauren Harvey, Charlene A. Audette, Alan Wilhelm, Chen Bai, Lingyun Rui, Rassol Laleau, (unknown), Olga Ab, Yulius Y. Setiady, Nicholas C. Yoder, Victor S. Goldmacher, Ravi Chari, Jan Pinkas, Thomas Chittenden	129
6	Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models 2018 ·Blood ·(unknown), (unknown), Julie A. Adams, (unknown), (unknown), (unknown), Callum M. Sloss, (unknown), Yelena Kovtun, Sharlene Adams, Eunice S. Wang	3
7	CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia 2017 ·Blood ·(unknown), Charlene A. Audette, Yelena Kovtun, Naval Daver, Sa A. Wang, Sherry Pierce, Sergej Konoplev, Jeffrey L. Jorgensen, Marina Konopleva, Patrick A. Zweidler‐McKay, Hagop M. Kantarjian, Elias Jabbour, Joseph D. Khoury	2
8	A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity 2016 ·Molecular Cancer Therapeutics ·Michael L. Miller, Nathan Fishkin, Wěi Li, Kathleen R. Whiteman, Yelena Kovtun, (unknown), Katie E. Archer, Erin K. Maloney, Charlene A. Audette, Michele Mayo, Alan Wilhelm, (unknown), Rajeeva Singh, Jan Pinkas, Victor S. Goldmacher, John M. Lambert, Ravi Chari	65
9	High-Affinity Accumulation of a Maytansinoid in Cells via Weak Tubulin Interaction 2015 ·PLoS ONE ·Victor S. Goldmacher, Charlene A. Audette, Yinghua Guan, Eriene-Heidi Sidhom, Jagesh V. Shah, Kathleen R. Whiteman, Yelena Kovtun	14
10	Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation 2015 ·Molecular Pharmaceutics ·Erica Hong, Hans K. Erickson, Robert J. Lutz, Kathleen R. Whiteman, Gregory E. Jones, Yelena Kovtun, Véronique Blanc, John M. Lambert	38
11	Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates 2011 ·Journal of Medicinal Chemistry ·Robert Y. Zhao, Sharon Wilhelm, Charlene A. Audette, Gregory E. Jones, Barbara A. Leece, Alexandru C. Lazar, Victor S. Goldmacher, Rajeeva Singh, Yelena Kovtun, Wayne C. Widdison, John M. Lambert, Ravi Chari	150
12	Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance 2010 ·Cancer Research ·Yelena Kovtun, Charlene A. Audette, Michele Mayo, Gregory E. Jones, (unknown), Erin K. Maloney, Hans K. Erickson, Xiuxia Sun, Sharon Wilhelm, Olga Ab, Katharine C. Lai, Wayne C. Widdison, Brenda Kellogg, Holly A. Johnson, Jan Pinkas, Robert J. Lutz, Rajeeva Singh, Victor S. Goldmacher, Ravi Chari	194
13	Evaluation of the cytotoxic potencies of the major maytansinoid metabolites of antibody maytansinoid conjugates detected in vitro and in preclinical mouse models 2008 ·Cancer Research ·Hans K. Erickson, Sharon Wilhelm, Wayne C. Widdison, Barbara A. Leece, Xiuxia Sun, Yelena Kovtun, (unknown), Ravi Chari	4
14	Linker selection in antibody-maytansinoid conjugates impacts bystander killing in mouse xenograft models 2007 ·Molecular Cancer Therapeutics ·Hans K. Erickson, Michele Mayo, Wayne C. Widdison, Charlene A. Audette, Yelena Kovtun, Ravi Chari, Robert Lutz, (unknown)	1
15	Cell killing by antibody–drug conjugates 2007 ·Cancer Letters ·Yelena Kovtun, Victor S. Goldmacher	174
16	Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing 2006 ·Cancer Research ·Hans K. Erickson, Peter U. Park, Wayne C. Widdison, Yelena Kovtun, Lisa M. Garrett, (unknown), Robert J. Lutz, Victor S. Goldmacher, Walter A. Blättler	421
17	Suppression of auxin signal transduction by a MAPK cascade in higher plants 1998 ·Nature ·Yelena Kovtun, Wan-Ling Chiu, (unknown), Jen Sheen	211
18	End-Product Control of Carbon Metabolism in Culture-Grown Sugar Beet Plants (Molecular and Physiological Evidence on Accelerated Leaf Development and Enhanced Gene Expression) 1995 ·PLANT PHYSIOLOGY ·Yelena Kovtun, Jaleh Daie	39
19	A new middle repetitive sequence of Nicotiana plumbaginifolia genome 1993 ·Plant Molecular Biology ·Yelena Kovtun, (unknown), (unknown)	4
20	Amplification of repetitive DNA from Nicotiana plumbaginifolia in asymmetric somatic hybrids between Nicotiana sylvestris and Nicotiana plumbaginifolia 1993 ·Theoretical and Applied Genetics ·Yelena Kovtun, (unknown), (unknown), Yuri Gleba	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact